Federal regulators have published a new batch of draft roadmaps outlining how drugmakers should develop generic versions of specific medicines, and the list includes products that many households already keep on hand: epinephrine, two ADHD stimulants, levothyroxine, ondansetron, and zolpidem.
The Federal Register notice, published Monday under docket number FDA-2007-D-0369, announces 23 new draft product-specific guidances and 25 revised ones. Comments are due by October 23.
